{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "pd.set_option('max_colwidth',5000)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "dev_knn_500 = pd.read_csv('../outputs/ddi_test_prompts_random_42.5.50.perm_4.KNN_500_balancedsubset.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>test_ready_prompt</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Sentence: Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.\\nDrug 1: bromocriptine mesylate\\nDrug 2: ergot alkaloids\\nInteraction: advice\\n\\nSentence: However, interactions may be expected, and UROXATRAL should NOT be used in combination with other alpha-blockers.\\nDrug 1: UROXATRAL\\nDrug 2: alpha-blockers\\nInteraction: advice\\n\\nSentence: Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.\\nDrug 1: fentanyl\\nDrug 2: beta blocker\\nInteraction: effect\\n\\nSentence: Population pharmacokinetic analyses revealed that MTX, NSAIDs, corticosteroids, and TNF blocking agents did not influence abatacept clearance.\\nDrug 1: NSAIDs\\nDrug 2: abatacept\\nInteraction: none\\n\\nSentence: Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with potassium-sparing diuretics.\\nDrug 1: nonsteroidal anti-inflammatory drugs\\nDrug 2: potassium-sparing diuretics\\nInteraction: effect\\n\\nSentence: The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.\\nDrug1: proton pump inhibitors\\nDrug2: SPRYCEL\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Sentence: Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.\\nDrug 1: diflunisal\\nDrug 2: methotrexate\\nInteraction: advice\\n\\nSentence: However, interactions may be expected, and UROXATRAL should NOT be used in combination with other alpha-blockers.\\nDrug 1: UROXATRAL\\nDrug 2: alpha-blockers\\nInteraction: advice\\n\\nSentence: Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because of the potential for additive effects on systemic beta-blockade.\\nDrug 1: Ocupress\\nDrug 2: beta-adrenergic blocking agent\\nInteraction: advice\\n\\nSentence: This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.\\nDrug 1: NSAIDs\\nDrug 2: ACE-inhibitors\\nInteraction: advice\\n\\nSentence: Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.\\nDrug 1: VIOXX\\nDrug 2: theophylline\\nInteraction: advice\\n\\nSentence: MAO inhibitors should be used with caution in patients receiving hydralazine.\\nDrug1: MAO inhibitors\\nDrug2: hydralazine\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Sentence: Nicardipine HCl usually does not alter the plasma levels of digoxin, however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine HCl is initiated.\\nDrug 1: digoxin\\nDrug 2: digoxin\\nInteraction: none\\n\\nSentence: For example, when vitamin K antagonists are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.\\nDrug 1: vitamin K antagonists\\nDrug 2: nilutamide\\nInteraction: advice\\n\\nSentence: Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.\\nDrug 1: VIOXX\\nDrug 2: theophylline\\nInteraction: advice\\n\\nSentence: Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.\\nDrug 1: diclofenac\\nDrug 2: warfarin\\nInteraction: advice\\n\\nSentence: If CEFOTAN and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated.\\nDrug 1: CEFOTAN\\nDrug 2: aminoglycoside\\nInteraction: effect\\n\\nSentence: Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.\\nDrug1: Cyclosporine\\nDrug2: Itraconazole\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Sentence: The concomitant use of diflunisal tablets and other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.\\nDrug 1: diflunisal\\nDrug 2: NSAIDs\\nInteraction: effect\\n\\nSentence: Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.\\nDrug 1: BREVIBLOC\\nDrug 2: warfarin\\nInteraction: advice\\n\\nSentence: Methotrexate - There is one report that methotrexate may decrease the possible effectiveness of supplemental L-glutamine for chemotherapy-induced mucositis.\\nDrug 1: methotrexate\\nDrug 2: L-glutamine\\nInteraction: effect\\n\\nSentence: CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.\\nDrug 1: CRIXIVAN\\nDrug 2: indinavir\\nInteraction: effect\\n\\nSentence: Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.\\nDrug 1: LEXAPRO\\nDrug 2: alcohol\\nInteraction: none\\n\\nSentence: There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.\\nDrug1: ORENCIA\\nDrug2: anakinra\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Sentence: Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.\\nDrug 1: almotriptan\\nDrug 2: almotriptan\\nInteraction: none\\n\\nSentence: If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.\\nDrug 1: indinavir\\nDrug 2: budesonide\\nInteraction: advice\\n\\nSentence: Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).\\nDrug 1: Gleevec\\nDrug 2: erythromycin\\nInteraction: advice\\n\\nSentence: Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.\\nDrug 1: dapsone\\nDrug 2: itraconazole\\nInteraction: none\\n\\nSentence: The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .\\nDrug 1: ENABLEX\\nDrug 2: ketoconazole\\nInteraction: advice\\n\\nSentence: Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.\\nDrug1: alosetron\\nDrug2: telithromycin\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Sentence: Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.\\nDrug 1: Antihistamines\\nDrug 2: tricyclic antidepressants\\nInteraction: effect\\n\\nSentence: Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.\\nDrug 1: benzodiazepines\\nDrug 2: barbiturates\\nInteraction: effect\\n\\nSentence: Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.\\nDrug 1: antidepressants\\nDrug 2: scopolamine\\nInteraction: none\\n\\nSentence: The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.\\nDrug 1: alcohol\\nDrug 2: narcotics\\nInteraction: none\\n\\nSentence: Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).\\nDrug 1: alcohol\\nDrug 2: antihistamines\\nInteraction: none\\n\\nSentence: Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.\\nDrug1: butorphanol\\nDrug2: antihistamines\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Sentence: As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.\\nDrug 1: nondepolarizing neuromuscular blocking agents\\nDrug 2: phenytoin\\nInteraction: effect\\n\\nSentence: 5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .\\nDrug 1: apomorphine\\nDrug 2: palonosetron\\nInteraction: advice\\n\\nSentence: 5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .\\nDrug 1: apomorphine\\nDrug 2: alosetron\\nInteraction: advice\\n\\nSentence: Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.\\nDrug 1: methysergide\\nDrug 2: naratriptan\\nInteraction: advice\\n\\nSentence: Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.\\nDrug 1: benzodiazepines\\nDrug 2: barbiturates\\nInteraction: effect\\n\\nSentence: When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.\\nDrug1: atropine\\nDrug2: pralidoxime\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Sentence: Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.\\nDrug 1: lithium\\nDrug 2: ACE inhibitors\\nInteraction: effect\\n\\nSentence: Anticoagulants: There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.\\nDrug 1: erythromycin\\nDrug 2: anticoagulants\\nInteraction: effect\\n\\nSentence: Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.\\nDrug 1: cytotoxic agents\\nDrug 2: allopurinol\\nInteraction: effect\\n\\nSentence: Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.\\nDrug 1: cyclophosphamide\\nDrug 2: allopurinol\\nInteraction: effect\\n\\nSentence: Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.\\nDrug 1: erythromycin\\nDrug 2: digoxin\\nInteraction: mechanism\\n\\nSentence: Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.\\nDrug1: ACE inhibitors\\nDrug2: lithium\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Sentence: The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.\\nDrug 1: alcohol\\nDrug 2: narcotics\\nInteraction: none\\n\\nSentence: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.\\nDrug 1: sulfonamides\\nDrug 2: monoamine oxidase inhibitors\\nInteraction: none\\n\\nSentence: Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.\\nDrug 1: Antihistamines\\nDrug 2: tricyclic antidepressants\\nInteraction: effect\\n\\nSentence: Other Drugs:Drugs such as quinidine, disopyramide, procainamide, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.\\nDrug 1: phenothiazines\\nDrug 2: antihistamines\\nInteraction: none\\n\\nSentence: Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.\\nDrug 1: xanthine derivatives\\nDrug 2: beta2-agonists.\\nInteraction: effect\\n\\nSentence: The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.\\nDrug1: benzodiazepines\\nDrug2: antidepressants\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Sentence: Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.\\nDrug 1: Lodine\\nDrug 2: thiazides\\nInteraction: effect\\n\\nSentence: Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.\\nDrug 1: tricyclic anti-depressants\\nDrug 2: bepridil hydrochloride\\nInteraction: effect\\n\\nSentence: As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.\\nDrug 1: nondepolarizing neuromuscular blocking agents\\nDrug 2: phenytoin\\nInteraction: effect\\n\\nSentence: In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.\\nDrug 1: Fondaparinux\\nDrug 2: piroxicam\\nInteraction: none\\n\\nSentence: This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder. \\nDrug 1: phenytoin\\nDrug 2: quetiapine\\nInteraction: mechanism\\n\\nSentence: In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.\\nDrug1: verapamil\\nDrug2: dofetilide\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Sentence: Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.\\nDrug 1: alcohol\\nDrug 2: DILAUDID\\nInteraction: effect\\n\\nSentence: Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.\\nDrug 1: narcotic analgesic\\nDrug 2: phenothiazines\\nInteraction: none\\n\\nSentence: Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).\\nDrug 1: Nabilone\\nDrug 2: alcohol\\nInteraction: advice\\n\\nSentence: Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).\\nDrug 1: Nabilone\\nDrug 2: CNS depressants\\nInteraction: advice\\n\\nSentence: Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).\\nDrug 1: Nabilone\\nDrug 2: barbiturates\\nInteraction: advice\\n\\nSentence: Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.\\nDrug1: alcohol\\nDrug2: hydrocodone\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Sentence: Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.\\nDrug 1: atropine sulfate\\nDrug 2: MAO inhibitors\\nInteraction: other\\n\\nSentence: Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.\\nDrug 1: mefenamic acid\\nDrug 2: mefenamic acid\\nInteraction: none\\n\\nSentence: Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.\\nDrug 1: Ketoconazole\\nDrug 2: vardenafil\\nInteraction: mechanism\\n\\nSentence: This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.\\nDrug 1: alprazolam\\nDrug 2: Fluvoxamine\\nInteraction: advice\\n\\nSentence: Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.\\nDrug 1: Naproxen\\nDrug 2: naproxen\\nInteraction: none\\n\\nSentence: Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.\\nDrug1: diflunisal\\nDrug2: acetaminophen\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Sentence: Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.\\nDrug 1: anesthetics\\nDrug 2: tricyclic antidepressants\\nInteraction: advice\\n\\nSentence: Other Drugs:Drugs such as quinidine, disopyramide, procainamide, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.\\nDrug 1: phenothiazines\\nDrug 2: antihistamines\\nInteraction: none\\n\\nSentence: Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and beta-blockers.)\\nDrug 1: clonidine\\nDrug 2: calcium channel blockers\\nInteraction: advice\\n\\nSentence: Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and beta-blockers.)\\nDrug 1: clonidine\\nDrug 2: beta-blockers\\nInteraction: advice\\n\\nSentence: Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.\\nDrug 1: LEXAPRO\\nDrug 2: alcohol\\nInteraction: none\\n\\nSentence: Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.\\nDrug1: tricyclic antidepressants\\nDrug2: guanethidine\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Sentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.\\nDrug 1: epinephrine\\nDrug 2: monoamine oxidase inhibitors\\nInteraction: effect\\n\\nSentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.\\nDrug 1: epinephrine\\nDrug 2: tricyclic antidepressants\\nInteraction: effect\\n\\nSentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.\\nDrug 1: norepinephrine\\nDrug 2: tricyclic antidepressants\\nInteraction: effect\\n\\nSentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.\\nDrug 1: epinephrine\\nDrug 2: tricyclic antidepressants\\nInteraction: effect\\n\\nSentence: Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .\\nDrug 1: doxapram\\nDrug 2: sympathomimetic\\nInteraction: effect\\n\\nSentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.\\nDrug1: norepinephrine\\nDrug2: monoamine oxidase inhibitors\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Sentence: Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.\\nDrug 1: antihistamines\\nDrug 2: heparin sodium\\nInteraction: effect\\n\\nSentence: Drug/ Laboratory Test Interactions Certain endocrine and liver function tests may be affected by estrogen-containing oral contraceptives.\\nDrug 1: estrogen\\nDrug 2: contraceptives\\nInteraction: none\\n\\nSentence: Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.\\nDrug 1: Diclofenac\\nDrug 2: diuretics\\nInteraction: effect\\n\\nSentence: Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.\\nDrug 1: xanthine derivatives\\nDrug 2: beta2-agonists.\\nInteraction: effect\\n\\nSentence: Acetazolamide may increase the effects of other folic acid antagonists.\\nDrug 1: Acetazolamide\\nDrug 2: folic acid antagonists\\nInteraction: effect\\n\\nSentence: Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.\\nDrug1: hormonal contraceptives\\nDrug2: coumarin derivatives\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Sentence: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.\\nDrug 1: erythromycin\\nDrug 2: dihydroergotamine\\nInteraction: effect\\n\\nSentence: Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.\\nDrug 1: methysergide\\nDrug 2: naratriptan\\nInteraction: advice\\n\\nSentence: Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.\\nDrug 1: erythromycin\\nDrug 2: digoxin\\nInteraction: mechanism\\n\\nSentence: Caution is advised in patients receiving concomitant high-dose aspirin and carbonic anhydrase inhibitors, as anorexia, tachypnea, lethargy and coma have been rarely reported due to a possible drug interaction.\\nDrug 1: aspirin\\nDrug 2: carbonic anhydrase inhibitors\\nInteraction: advice\\n\\nSentence: There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam.\\nDrug 1: loxapine\\nDrug 2: lorazepam\\nInteraction: effect\\n\\nSentence: Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.\\nDrug1: erythromycin\\nDrug2: ergotamine\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Sentence: Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.\\nDrug 1: Antihistamines\\nDrug 2: tricyclic antidepressants\\nInteraction: effect\\n\\nSentence: Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.\\nDrug 1: benzodiazepines\\nDrug 2: barbiturates\\nInteraction: effect\\n\\nSentence: Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.\\nDrug 1: antidepressants\\nDrug 2: scopolamine\\nInteraction: none\\n\\nSentence: The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.\\nDrug 1: alcohol\\nDrug 2: narcotics\\nInteraction: none\\n\\nSentence: Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).\\nDrug 1: alcohol\\nDrug 2: antihistamines\\nInteraction: none\\n\\nSentence: Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.\\nDrug1: butorphanol\\nDrug2: tranquilizers\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Sentence: Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.\\nDrug 1: thiazides\\nDrug 2: amphetamine\\nInteraction: mechanism\\n\\nSentence: Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.\\nDrug 1: tetracycline\\nDrug 2: digoxin\\nInteraction: mechanism\\n\\nSentence: Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.\\nDrug 1: Phenobarbital\\nDrug 2: vitamin D\\nInteraction: none\\n\\nSentence: Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).\\nDrug 1: Quinidine\\nDrug 2: quinidine\\nInteraction: none\\n\\nSentence: Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.\\nDrug 1: acetaminophen\\nDrug 2: BUSULFEX\\nInteraction: mechanism\\n\\nSentence: Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.\\nDrug1: allopurinol\\nDrug2: chlorpropamide\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Sentence: Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.\\nDrug 1: paclitaxel\\nDrug 2: doxorubicin\\nInteraction: mechanism\\n\\nSentence: Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.\\nDrug 1: tetracycline\\nDrug 2: digoxin\\nInteraction: mechanism\\n\\nSentence: Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.\\nDrug 1: phenytoin\\nDrug 2: corticosteroids\\nInteraction: mechanism\\n\\nSentence: Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.\\nDrug 1: HMG-CoA reductase inhibitor\\nDrug 2: ketoconazole\\nInteraction: advice\\n\\nSentence: As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.\\nDrug 1: nondepolarizing neuromuscular blocking agents\\nDrug 2: phenytoin\\nInteraction: effect\\n\\nSentence: Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.\\nDrug1: rifampin\\nDrug2: corticosteroids\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Sentence: Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. \\nDrug 1: digoxin\\nDrug 2: digoxin\\nInteraction: none\\n\\nSentence: Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.\\nDrug 1: bosentan\\nDrug 2: glyburide\\nInteraction: mechanism\\n\\nSentence: Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.\\nDrug 1: Ketoconazole\\nDrug 2: vardenafil\\nInteraction: mechanism\\n\\nSentence: Phenytoin: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.\\nDrug 1: Phenytoin\\nDrug 2: lomefloxacin\\nInteraction: none\\n\\nSentence: Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.\\nDrug 1: atorvastatin\\nDrug 2: contraceptive\\nInteraction: mechanism\\n\\nSentence: (See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.\\nDrug1: Femara\\nDrug2: tamoxifen\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Sentence: Phenytoin: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.\\nDrug 1: Phenytoin\\nDrug 2: lomefloxacin\\nInteraction: none\\n\\nSentence: Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.\\nDrug 1: mefenamic acid\\nDrug 2: mefenamic acid\\nInteraction: none\\n\\nSentence: Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.\\nDrug 1: Ketoconazole\\nDrug 2: vardenafil\\nInteraction: mechanism\\n\\nSentence: When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.\\nDrug 1: BREVIBLOC\\nDrug 2: morphine\\nInteraction: mechanism\\n\\nSentence: Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.\\nDrug 1: ketoconazole\\nDrug 2: lapatinib\\nInteraction: mechanism\\n\\nSentence: In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.\\nDrug1: nitrates\\nDrug2: vardenafil\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.\\nDrug1: EQUETROTM\\nDrug2: nortriptyline\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Sentence: Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.\\nDrug 1: Ketoconazole\\nDrug 2: vardenafil\\nInteraction: mechanism\\n\\nSentence: Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.\\nDrug 1: aspirin\\nDrug 2: valdecoxib\\nInteraction: effect\\n\\nSentence: Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. \\nDrug 1: digoxin\\nDrug 2: digoxin\\nInteraction: none\\n\\nSentence: Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.\\nDrug 1: dextromethorphan\\nDrug 2: valdecoxib\\nInteraction: mechanism\\n\\nSentence: When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.\\nDrug 1: BREVIBLOC\\nDrug 2: morphine\\nInteraction: mechanism\\n\\nSentence: Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.\\nDrug1: anastrozole\\nDrug2: tamoxifen\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.\\nDrug1: EQUETROTM\\nDrug2: felbamate\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.\\nDrug1: EQUETROTM\\nDrug2: haloperidol\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Sentence: - Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine\\nDrug 1: phenytoin\\nDrug 2: alcohol\\nInteraction: mechanism\\n\\nSentence: May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;\\nDrug 1: colestipol\\nDrug 2: thiazide diuretics\\nInteraction: effect\\n\\nSentence: Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol\\nDrug 1: Tricyclic antidepressants\\nDrug 2: tramadol\\nInteraction: effect\\n\\nSentence: Enhanced theophylline clearance secondary to phenytoin therapy.\\r\\n\\nDrug 1: theophylline\\nDrug 2: phenytoin\\nInteraction: mechanism\\n\\nSentence: Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;\\nDrug 1: Cyclopentolate\\nDrug 2: carbachol\\nInteraction: effect\\n\\nSentence: Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;\\nDrug1: Amphetamines\\nDrug2: phenobarbital\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Sentence: When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.\\nDrug 1: BREVIBLOC\\nDrug 2: morphine\\nInteraction: mechanism\\n\\nSentence: Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.\\nDrug 1: Naproxen\\nDrug 2: naproxen\\nInteraction: none\\n\\nSentence: Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.\\nDrug 1: diflunisal\\nDrug 2: hydrochlorothiazide\\nInteraction: mechanism\\n\\nSentence: Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. \\nDrug 1: digoxin\\nDrug 2: digoxin\\nInteraction: none\\n\\nSentence: Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.\\nDrug 1: Acetazolamide\\nDrug 2: amphetamine\\nInteraction: mechanism\\n\\nSentence: Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.\\nDrug1: Norpace\\nDrug2: quinidine\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Sentence: Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.\\nDrug 1: ketoconazole\\nDrug 2: lapatinib\\nInteraction: mechanism\\n\\nSentence: Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.\\nDrug 1: Ketoconazole\\nDrug 2: vardenafil\\nInteraction: mechanism\\n\\nSentence: Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).\\nDrug 1: rifampin\\nDrug 2: Gleevec\\nInteraction: mechanism\\n\\nSentence: Phenytoin: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.\\nDrug 1: Phenytoin\\nDrug 2: lomefloxacin\\nInteraction: none\\n\\nSentence: Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.\\nDrug 1: mefenamic acid\\nDrug 2: mefenamic acid\\nInteraction: none\\n\\nSentence: Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.\\nDrug1: tolbutamide\\nDrug2: Aprepitant\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: perchlorate\\nDrug2: iodine-containing compounds\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: estrogens\\nInteraction: none\\n\\nSentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\\nDrug 1: quinine\\nDrug 2: saquinavir\\nInteraction: mechanism\\n\\nSentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\\nDrug 1: triazolam\\nDrug 2: saquinavir\\nInteraction: mechanism\\n\\nSentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\\nDrug 1: disulfiram\\nDrug 2: fluoxetine\\nInteraction: none\\n\\nSentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\\nDrug 1: phenytoin\\nDrug 2: disulfiram\\nInteraction: mechanism\\n\\nSentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug1: clofibrate\\nDrug2: 5-fluorouracil\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: estrogens\\nInteraction: none\\n\\nSentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\\nDrug 1: quinine\\nDrug 2: saquinavir\\nInteraction: mechanism\\n\\nSentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\\nDrug 1: triazolam\\nDrug 2: saquinavir\\nInteraction: mechanism\\n\\nSentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\\nDrug 1: disulfiram\\nDrug 2: fluoxetine\\nInteraction: none\\n\\nSentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\\nDrug 1: phenytoin\\nDrug 2: disulfiram\\nInteraction: mechanism\\n\\nSentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug1: androgens\\nDrug2: 5-fluorouracil\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: thiocyanate\\nDrug2: somatostatin analogs\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>Sentence: Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.\\nDrug 1: xanthine derivatives\\nDrug 2: beta2-agonists.\\nInteraction: effect\\n\\nSentence: Other Drugs:Drugs such as quinidine, disopyramide, procainamide, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.\\nDrug 1: phenothiazines\\nDrug 2: antihistamines\\nInteraction: none\\n\\nSentence: Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.\\nDrug 1: NSAIDs\\nDrug 2: furosemide\\nInteraction: effect\\n\\nSentence: Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.\\nDrug 1: methysergide\\nDrug 2: naratriptan\\nInteraction: advice\\n\\nSentence: Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.\\nDrug 1: antihistamines\\nDrug 2: heparin sodium\\nInteraction: effect\\n\\nSentence: Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.\\nDrug1: spironolactone\\nDrug2: triamterene\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>Sentence: Methenamine therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.\\nDrug 1: amphetamines\\nDrug 2: methenamine\\nInteraction: mechanism\\n\\nSentence: Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.\\nDrug 1: atropine sulfate\\nDrug 2: MAO inhibitors\\nInteraction: other\\n\\nSentence: Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.\\nDrug 1: LEXAPRO\\nDrug 2: alcohol\\nInteraction: none\\n\\nSentence: Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.\\nDrug 1: psychotropic medications\\nDrug 2: LEXAPRO\\nInteraction: advice\\n\\nSentence: Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.\\nDrug 1: amphetamines\\nDrug 2: acidifying agents\\nInteraction: mechanism\\n\\nSentence: MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .\\nDrug1: MAO Inhibitors\\nDrug2: MAO inhibitor\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: amiodarone\\nDrug2: heparin\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: estrogens\\nInteraction: none\\n\\nSentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\\nDrug 1: quinine\\nDrug 2: saquinavir\\nInteraction: mechanism\\n\\nSentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\\nDrug 1: triazolam\\nDrug 2: saquinavir\\nInteraction: mechanism\\n\\nSentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\\nDrug 1: disulfiram\\nDrug 2: fluoxetine\\nInteraction: none\\n\\nSentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\\nDrug 1: phenytoin\\nDrug 2: disulfiram\\nInteraction: mechanism\\n\\nSentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug1: glucocorticoids\\nDrug2: tamoxifen\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: estrogens\\nInteraction: none\\n\\nSentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\\nDrug 1: quinine\\nDrug 2: saquinavir\\nInteraction: mechanism\\n\\nSentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\\nDrug 1: triazolam\\nDrug 2: saquinavir\\nInteraction: mechanism\\n\\nSentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\\nDrug 1: disulfiram\\nDrug 2: fluoxetine\\nInteraction: none\\n\\nSentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\\nDrug 1: phenytoin\\nDrug 2: disulfiram\\nInteraction: mechanism\\n\\nSentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug1: meclofenamic acid\\nDrug2: tamoxifen\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>Sentence: Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.\\nDrug 1: itraconazole\\nDrug 2: gefitinib\\nInteraction: mechanism\\n\\nSentence: Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).\\nDrug 1: Gleevec\\nDrug 2: erythromycin\\nInteraction: advice\\n\\nSentence: Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.\\nDrug 1: esomeprazole\\nDrug 2: diazepam\\nInteraction: mechanism\\n\\nSentence: Based on the chemical resemblance of itraconazole and ketoconazole, coadministration of astemizole with itraconazole is contraindicated.\\nDrug 1: astemizole\\nDrug 2: itraconazole\\nInteraction: advice\\n\\nSentence: The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .\\nDrug 1: ENABLEX\\nDrug 2: ketoconazole\\nInteraction: advice\\n\\nSentence: Fluconazole and Ketoconazole: Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.\\nDrug1: Fluconazole\\nDrug2: Ketoconazole\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: aminoglutethimide\\nDrug2: b-adrenergic blocking agents\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: aminoglutethimide\\nDrug2: nitroprusside\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: amiodarone\\nDrug2: metoclopramide\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: perchlorate\\nDrug2: chloral hydrate\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: estrogens\\nInteraction: none\\n\\nSentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\\nDrug 1: quinine\\nDrug 2: saquinavir\\nInteraction: mechanism\\n\\nSentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\\nDrug 1: triazolam\\nDrug 2: saquinavir\\nInteraction: mechanism\\n\\nSentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\\nDrug 1: disulfiram\\nDrug 2: fluoxetine\\nInteraction: none\\n\\nSentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\\nDrug 1: phenytoin\\nDrug 2: disulfiram\\nInteraction: mechanism\\n\\nSentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug1: asparaginase\\nDrug2: furosemide\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>Sentence: Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.\\nDrug 1: clozapine\\nDrug 2: encainide\\nInteraction: advice\\n\\nSentence: Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.\\nDrug 1: clozapine\\nDrug 2: propafenone\\nInteraction: advice\\n\\nSentence: Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.\\nDrug 1: fluoxetine\\nDrug 2: antipsychotics\\nInteraction: none\\n\\nSentence: Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.\\nDrug 1: risperidone\\nDrug 2: metoprolol\\nInteraction: none\\n\\nSentence: Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.\\nDrug 1: bupropion\\nDrug 2: nortriptyline\\nInteraction: advice\\n\\nSentence: Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.\\nDrug1: carbamazepine\\nDrug2: encainide\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>Sentence: Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.\\nDrug 1: INSPRA\\nDrug 2: lithium\\nInteraction: advice\\n\\nSentence: Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.\\nDrug 1: VIOXX\\nDrug 2: theophylline\\nInteraction: advice\\n\\nSentence: Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.\\nDrug 1: methotrexate\\nDrug 2: ciprofloxacin\\nInteraction: advice\\n\\nSentence: Nicardipine HCl usually does not alter the plasma levels of digoxin, however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine HCl is initiated.\\nDrug 1: digoxin\\nDrug 2: digoxin\\nInteraction: none\\n\\nSentence: Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.\\nDrug 1: Vitamin D\\nDrug 2: digitalis\\nInteraction: advice\\n\\nSentence: Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice.\\nDrug1: lithium\\nDrug2: lithium\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: antithyroid drugs\\nDrug2: levodopa\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: thiocyanate\\nDrug2: levodopa\\nInteraction:</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>Sentence: 5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .\\nDrug 1: apomorphine\\nDrug 2: palonosetron\\nInteraction: advice\\n\\nSentence: 5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .\\nDrug 1: apomorphine\\nDrug 2: alosetron\\nInteraction: advice\\n\\nSentence: plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.\\nDrug 1: barbiturates\\nDrug 2: CMI\\nInteraction: mechanism\\n\\nSentence: plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.\\nDrug 1: tricyclic antidepressants\\nDrug 2: cimetidine\\nInteraction: mechanism\\n\\nSentence: The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.\\nDrug 1: antipsychotic drug\\nDrug 2: chlorpromazine\\nInteraction: none\\n\\nSentence: Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).\\nDrug1: Zarontin\\nDrug2: antiepileptic drugs\\nInteraction:</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        test_ready_prompt\n",
       "0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Sentence: Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.\\nDrug 1: bromocriptine mesylate\\nDrug 2: ergot alkaloids\\nInteraction: advice\\n\\nSentence: However, interactions may be expected, and UROXATRAL should NOT be used in combination with other alpha-blockers.\\nDrug 1: UROXATRAL\\nDrug 2: alpha-blockers\\nInteraction: advice\\n\\nSentence: Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.\\nDrug 1: fentanyl\\nDrug 2: beta blocker\\nInteraction: effect\\n\\nSentence: Population pharmacokinetic analyses revealed that MTX, NSAIDs, corticosteroids, and TNF blocking agents did not influence abatacept clearance.\\nDrug 1: NSAIDs\\nDrug 2: abatacept\\nInteraction: none\\n\\nSentence: Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with potassium-sparing diuretics.\\nDrug 1: nonsteroidal anti-inflammatory drugs\\nDrug 2: potassium-sparing diuretics\\nInteraction: effect\\n\\nSentence: The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.\\nDrug1: proton pump inhibitors\\nDrug2: SPRYCEL\\nInteraction:\n",
       "1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Sentence: Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.\\nDrug 1: diflunisal\\nDrug 2: methotrexate\\nInteraction: advice\\n\\nSentence: However, interactions may be expected, and UROXATRAL should NOT be used in combination with other alpha-blockers.\\nDrug 1: UROXATRAL\\nDrug 2: alpha-blockers\\nInteraction: advice\\n\\nSentence: Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because of the potential for additive effects on systemic beta-blockade.\\nDrug 1: Ocupress\\nDrug 2: beta-adrenergic blocking agent\\nInteraction: advice\\n\\nSentence: This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.\\nDrug 1: NSAIDs\\nDrug 2: ACE-inhibitors\\nInteraction: advice\\n\\nSentence: Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.\\nDrug 1: VIOXX\\nDrug 2: theophylline\\nInteraction: advice\\n\\nSentence: MAO inhibitors should be used with caution in patients receiving hydralazine.\\nDrug1: MAO inhibitors\\nDrug2: hydralazine\\nInteraction:\n",
       "2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Sentence: Nicardipine HCl usually does not alter the plasma levels of digoxin, however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine HCl is initiated.\\nDrug 1: digoxin\\nDrug 2: digoxin\\nInteraction: none\\n\\nSentence: For example, when vitamin K antagonists are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.\\nDrug 1: vitamin K antagonists\\nDrug 2: nilutamide\\nInteraction: advice\\n\\nSentence: Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.\\nDrug 1: VIOXX\\nDrug 2: theophylline\\nInteraction: advice\\n\\nSentence: Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.\\nDrug 1: diclofenac\\nDrug 2: warfarin\\nInteraction: advice\\n\\nSentence: If CEFOTAN and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated.\\nDrug 1: CEFOTAN\\nDrug 2: aminoglycoside\\nInteraction: effect\\n\\nSentence: Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.\\nDrug1: Cyclosporine\\nDrug2: Itraconazole\\nInteraction:\n",
       "3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Sentence: The concomitant use of diflunisal tablets and other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.\\nDrug 1: diflunisal\\nDrug 2: NSAIDs\\nInteraction: effect\\n\\nSentence: Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.\\nDrug 1: BREVIBLOC\\nDrug 2: warfarin\\nInteraction: advice\\n\\nSentence: Methotrexate - There is one report that methotrexate may decrease the possible effectiveness of supplemental L-glutamine for chemotherapy-induced mucositis.\\nDrug 1: methotrexate\\nDrug 2: L-glutamine\\nInteraction: effect\\n\\nSentence: CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.\\nDrug 1: CRIXIVAN\\nDrug 2: indinavir\\nInteraction: effect\\n\\nSentence: Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.\\nDrug 1: LEXAPRO\\nDrug 2: alcohol\\nInteraction: none\\n\\nSentence: There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.\\nDrug1: ORENCIA\\nDrug2: anakinra\\nInteraction:\n",
       "4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sentence: Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.\\nDrug 1: almotriptan\\nDrug 2: almotriptan\\nInteraction: none\\n\\nSentence: If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.\\nDrug 1: indinavir\\nDrug 2: budesonide\\nInteraction: advice\\n\\nSentence: Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).\\nDrug 1: Gleevec\\nDrug 2: erythromycin\\nInteraction: advice\\n\\nSentence: Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.\\nDrug 1: dapsone\\nDrug 2: itraconazole\\nInteraction: none\\n\\nSentence: The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .\\nDrug 1: ENABLEX\\nDrug 2: ketoconazole\\nInteraction: advice\\n\\nSentence: Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.\\nDrug1: alosetron\\nDrug2: telithromycin\\nInteraction:\n",
       "5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Sentence: Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.\\nDrug 1: Antihistamines\\nDrug 2: tricyclic antidepressants\\nInteraction: effect\\n\\nSentence: Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.\\nDrug 1: benzodiazepines\\nDrug 2: barbiturates\\nInteraction: effect\\n\\nSentence: Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.\\nDrug 1: antidepressants\\nDrug 2: scopolamine\\nInteraction: none\\n\\nSentence: The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.\\nDrug 1: alcohol\\nDrug 2: narcotics\\nInteraction: none\\n\\nSentence: Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).\\nDrug 1: alcohol\\nDrug 2: antihistamines\\nInteraction: none\\n\\nSentence: Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.\\nDrug1: butorphanol\\nDrug2: antihistamines\\nInteraction:\n",
       "6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Sentence: As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.\\nDrug 1: nondepolarizing neuromuscular blocking agents\\nDrug 2: phenytoin\\nInteraction: effect\\n\\nSentence: 5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .\\nDrug 1: apomorphine\\nDrug 2: palonosetron\\nInteraction: advice\\n\\nSentence: 5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .\\nDrug 1: apomorphine\\nDrug 2: alosetron\\nInteraction: advice\\n\\nSentence: Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.\\nDrug 1: methysergide\\nDrug 2: naratriptan\\nInteraction: advice\\n\\nSentence: Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.\\nDrug 1: benzodiazepines\\nDrug 2: barbiturates\\nInteraction: effect\\n\\nSentence: When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.\\nDrug1: atropine\\nDrug2: pralidoxime\\nInteraction:\n",
       "7                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Sentence: Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.\\nDrug 1: lithium\\nDrug 2: ACE inhibitors\\nInteraction: effect\\n\\nSentence: Anticoagulants: There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.\\nDrug 1: erythromycin\\nDrug 2: anticoagulants\\nInteraction: effect\\n\\nSentence: Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.\\nDrug 1: cytotoxic agents\\nDrug 2: allopurinol\\nInteraction: effect\\n\\nSentence: Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.\\nDrug 1: cyclophosphamide\\nDrug 2: allopurinol\\nInteraction: effect\\n\\nSentence: Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.\\nDrug 1: erythromycin\\nDrug 2: digoxin\\nInteraction: mechanism\\n\\nSentence: Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.\\nDrug1: ACE inhibitors\\nDrug2: lithium\\nInteraction:\n",
       "8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Sentence: The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.\\nDrug 1: alcohol\\nDrug 2: narcotics\\nInteraction: none\\n\\nSentence: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.\\nDrug 1: sulfonamides\\nDrug 2: monoamine oxidase inhibitors\\nInteraction: none\\n\\nSentence: Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.\\nDrug 1: Antihistamines\\nDrug 2: tricyclic antidepressants\\nInteraction: effect\\n\\nSentence: Other Drugs:Drugs such as quinidine, disopyramide, procainamide, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.\\nDrug 1: phenothiazines\\nDrug 2: antihistamines\\nInteraction: none\\n\\nSentence: Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.\\nDrug 1: xanthine derivatives\\nDrug 2: beta2-agonists.\\nInteraction: effect\\n\\nSentence: The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.\\nDrug1: benzodiazepines\\nDrug2: antidepressants\\nInteraction:\n",
       "9                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sentence: Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.\\nDrug 1: Lodine\\nDrug 2: thiazides\\nInteraction: effect\\n\\nSentence: Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.\\nDrug 1: tricyclic anti-depressants\\nDrug 2: bepridil hydrochloride\\nInteraction: effect\\n\\nSentence: As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.\\nDrug 1: nondepolarizing neuromuscular blocking agents\\nDrug 2: phenytoin\\nInteraction: effect\\n\\nSentence: In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.\\nDrug 1: Fondaparinux\\nDrug 2: piroxicam\\nInteraction: none\\n\\nSentence: This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder. \\nDrug 1: phenytoin\\nDrug 2: quetiapine\\nInteraction: mechanism\\n\\nSentence: In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.\\nDrug1: verapamil\\nDrug2: dofetilide\\nInteraction:\n",
       "10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Sentence: Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.\\nDrug 1: alcohol\\nDrug 2: DILAUDID\\nInteraction: effect\\n\\nSentence: Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.\\nDrug 1: narcotic analgesic\\nDrug 2: phenothiazines\\nInteraction: none\\n\\nSentence: Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).\\nDrug 1: Nabilone\\nDrug 2: alcohol\\nInteraction: advice\\n\\nSentence: Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).\\nDrug 1: Nabilone\\nDrug 2: CNS depressants\\nInteraction: advice\\n\\nSentence: Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).\\nDrug 1: Nabilone\\nDrug 2: barbiturates\\nInteraction: advice\\n\\nSentence: Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.\\nDrug1: alcohol\\nDrug2: hydrocodone\\nInteraction:\n",
       "11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Sentence: Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.\\nDrug 1: atropine sulfate\\nDrug 2: MAO inhibitors\\nInteraction: other\\n\\nSentence: Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.\\nDrug 1: mefenamic acid\\nDrug 2: mefenamic acid\\nInteraction: none\\n\\nSentence: Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.\\nDrug 1: Ketoconazole\\nDrug 2: vardenafil\\nInteraction: mechanism\\n\\nSentence: This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.\\nDrug 1: alprazolam\\nDrug 2: Fluvoxamine\\nInteraction: advice\\n\\nSentence: Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.\\nDrug 1: Naproxen\\nDrug 2: naproxen\\nInteraction: none\\n\\nSentence: Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.\\nDrug1: diflunisal\\nDrug2: acetaminophen\\nInteraction:\n",
       "12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Sentence: Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.\\nDrug 1: anesthetics\\nDrug 2: tricyclic antidepressants\\nInteraction: advice\\n\\nSentence: Other Drugs:Drugs such as quinidine, disopyramide, procainamide, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.\\nDrug 1: phenothiazines\\nDrug 2: antihistamines\\nInteraction: none\\n\\nSentence: Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and beta-blockers.)\\nDrug 1: clonidine\\nDrug 2: calcium channel blockers\\nInteraction: advice\\n\\nSentence: Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and beta-blockers.)\\nDrug 1: clonidine\\nDrug 2: beta-blockers\\nInteraction: advice\\n\\nSentence: Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.\\nDrug 1: LEXAPRO\\nDrug 2: alcohol\\nInteraction: none\\n\\nSentence: Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.\\nDrug1: tricyclic antidepressants\\nDrug2: guanethidine\\nInteraction:\n",
       "13                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Sentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.\\nDrug 1: epinephrine\\nDrug 2: monoamine oxidase inhibitors\\nInteraction: effect\\n\\nSentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.\\nDrug 1: epinephrine\\nDrug 2: tricyclic antidepressants\\nInteraction: effect\\n\\nSentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.\\nDrug 1: norepinephrine\\nDrug 2: tricyclic antidepressants\\nInteraction: effect\\n\\nSentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.\\nDrug 1: epinephrine\\nDrug 2: tricyclic antidepressants\\nInteraction: effect\\n\\nSentence: Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .\\nDrug 1: doxapram\\nDrug 2: sympathomimetic\\nInteraction: effect\\n\\nSentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.\\nDrug1: norepinephrine\\nDrug2: monoamine oxidase inhibitors\\nInteraction:\n",
       "14                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Sentence: Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.\\nDrug 1: antihistamines\\nDrug 2: heparin sodium\\nInteraction: effect\\n\\nSentence: Drug/ Laboratory Test Interactions Certain endocrine and liver function tests may be affected by estrogen-containing oral contraceptives.\\nDrug 1: estrogen\\nDrug 2: contraceptives\\nInteraction: none\\n\\nSentence: Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.\\nDrug 1: Diclofenac\\nDrug 2: diuretics\\nInteraction: effect\\n\\nSentence: Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.\\nDrug 1: xanthine derivatives\\nDrug 2: beta2-agonists.\\nInteraction: effect\\n\\nSentence: Acetazolamide may increase the effects of other folic acid antagonists.\\nDrug 1: Acetazolamide\\nDrug 2: folic acid antagonists\\nInteraction: effect\\n\\nSentence: Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.\\nDrug1: hormonal contraceptives\\nDrug2: coumarin derivatives\\nInteraction:\n",
       "15                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Sentence: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.\\nDrug 1: erythromycin\\nDrug 2: dihydroergotamine\\nInteraction: effect\\n\\nSentence: Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.\\nDrug 1: methysergide\\nDrug 2: naratriptan\\nInteraction: advice\\n\\nSentence: Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.\\nDrug 1: erythromycin\\nDrug 2: digoxin\\nInteraction: mechanism\\n\\nSentence: Caution is advised in patients receiving concomitant high-dose aspirin and carbonic anhydrase inhibitors, as anorexia, tachypnea, lethargy and coma have been rarely reported due to a possible drug interaction.\\nDrug 1: aspirin\\nDrug 2: carbonic anhydrase inhibitors\\nInteraction: advice\\n\\nSentence: There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam.\\nDrug 1: loxapine\\nDrug 2: lorazepam\\nInteraction: effect\\n\\nSentence: Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.\\nDrug1: erythromycin\\nDrug2: ergotamine\\nInteraction:\n",
       "16                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Sentence: Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.\\nDrug 1: Antihistamines\\nDrug 2: tricyclic antidepressants\\nInteraction: effect\\n\\nSentence: Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.\\nDrug 1: benzodiazepines\\nDrug 2: barbiturates\\nInteraction: effect\\n\\nSentence: Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.\\nDrug 1: antidepressants\\nDrug 2: scopolamine\\nInteraction: none\\n\\nSentence: The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.\\nDrug 1: alcohol\\nDrug 2: narcotics\\nInteraction: none\\n\\nSentence: Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).\\nDrug 1: alcohol\\nDrug 2: antihistamines\\nInteraction: none\\n\\nSentence: Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.\\nDrug1: butorphanol\\nDrug2: tranquilizers\\nInteraction:\n",
       "17                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Sentence: Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.\\nDrug 1: thiazides\\nDrug 2: amphetamine\\nInteraction: mechanism\\n\\nSentence: Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.\\nDrug 1: tetracycline\\nDrug 2: digoxin\\nInteraction: mechanism\\n\\nSentence: Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.\\nDrug 1: Phenobarbital\\nDrug 2: vitamin D\\nInteraction: none\\n\\nSentence: Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).\\nDrug 1: Quinidine\\nDrug 2: quinidine\\nInteraction: none\\n\\nSentence: Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.\\nDrug 1: acetaminophen\\nDrug 2: BUSULFEX\\nInteraction: mechanism\\n\\nSentence: Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.\\nDrug1: allopurinol\\nDrug2: chlorpropamide\\nInteraction:\n",
       "18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Sentence: Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.\\nDrug 1: paclitaxel\\nDrug 2: doxorubicin\\nInteraction: mechanism\\n\\nSentence: Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.\\nDrug 1: tetracycline\\nDrug 2: digoxin\\nInteraction: mechanism\\n\\nSentence: Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.\\nDrug 1: phenytoin\\nDrug 2: corticosteroids\\nInteraction: mechanism\\n\\nSentence: Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.\\nDrug 1: HMG-CoA reductase inhibitor\\nDrug 2: ketoconazole\\nInteraction: advice\\n\\nSentence: As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.\\nDrug 1: nondepolarizing neuromuscular blocking agents\\nDrug 2: phenytoin\\nInteraction: effect\\n\\nSentence: Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.\\nDrug1: rifampin\\nDrug2: corticosteroids\\nInteraction:\n",
       "19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Sentence: Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. \\nDrug 1: digoxin\\nDrug 2: digoxin\\nInteraction: none\\n\\nSentence: Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.\\nDrug 1: bosentan\\nDrug 2: glyburide\\nInteraction: mechanism\\n\\nSentence: Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.\\nDrug 1: Ketoconazole\\nDrug 2: vardenafil\\nInteraction: mechanism\\n\\nSentence: Phenytoin: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.\\nDrug 1: Phenytoin\\nDrug 2: lomefloxacin\\nInteraction: none\\n\\nSentence: Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.\\nDrug 1: atorvastatin\\nDrug 2: contraceptive\\nInteraction: mechanism\\n\\nSentence: (See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.\\nDrug1: Femara\\nDrug2: tamoxifen\\nInteraction:\n",
       "20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Sentence: Phenytoin: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.\\nDrug 1: Phenytoin\\nDrug 2: lomefloxacin\\nInteraction: none\\n\\nSentence: Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.\\nDrug 1: mefenamic acid\\nDrug 2: mefenamic acid\\nInteraction: none\\n\\nSentence: Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.\\nDrug 1: Ketoconazole\\nDrug 2: vardenafil\\nInteraction: mechanism\\n\\nSentence: When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.\\nDrug 1: BREVIBLOC\\nDrug 2: morphine\\nInteraction: mechanism\\n\\nSentence: Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.\\nDrug 1: ketoconazole\\nDrug 2: lapatinib\\nInteraction: mechanism\\n\\nSentence: In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.\\nDrug1: nitrates\\nDrug2: vardenafil\\nInteraction:\n",
       "21                                                                                                                                Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.\\nDrug1: EQUETROTM\\nDrug2: nortriptyline\\nInteraction:\n",
       "22                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Sentence: Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.\\nDrug 1: Ketoconazole\\nDrug 2: vardenafil\\nInteraction: mechanism\\n\\nSentence: Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.\\nDrug 1: aspirin\\nDrug 2: valdecoxib\\nInteraction: effect\\n\\nSentence: Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. \\nDrug 1: digoxin\\nDrug 2: digoxin\\nInteraction: none\\n\\nSentence: Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.\\nDrug 1: dextromethorphan\\nDrug 2: valdecoxib\\nInteraction: mechanism\\n\\nSentence: When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.\\nDrug 1: BREVIBLOC\\nDrug 2: morphine\\nInteraction: mechanism\\n\\nSentence: Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.\\nDrug1: anastrozole\\nDrug2: tamoxifen\\nInteraction:\n",
       "23                                                                                                                                    Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.\\nDrug1: EQUETROTM\\nDrug2: felbamate\\nInteraction:\n",
       "24                                                                                                                                  Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.\\nDrug1: EQUETROTM\\nDrug2: haloperidol\\nInteraction:\n",
       "25                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Sentence: - Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine\\nDrug 1: phenytoin\\nDrug 2: alcohol\\nInteraction: mechanism\\n\\nSentence: May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;\\nDrug 1: colestipol\\nDrug 2: thiazide diuretics\\nInteraction: effect\\n\\nSentence: Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol\\nDrug 1: Tricyclic antidepressants\\nDrug 2: tramadol\\nInteraction: effect\\n\\nSentence: Enhanced theophylline clearance secondary to phenytoin therapy.\\r\\n\\nDrug 1: theophylline\\nDrug 2: phenytoin\\nInteraction: mechanism\\n\\nSentence: Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;\\nDrug 1: Cyclopentolate\\nDrug 2: carbachol\\nInteraction: effect\\n\\nSentence: Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;\\nDrug1: Amphetamines\\nDrug2: phenobarbital\\nInteraction:\n",
       "26                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Sentence: When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.\\nDrug 1: BREVIBLOC\\nDrug 2: morphine\\nInteraction: mechanism\\n\\nSentence: Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.\\nDrug 1: Naproxen\\nDrug 2: naproxen\\nInteraction: none\\n\\nSentence: Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.\\nDrug 1: diflunisal\\nDrug 2: hydrochlorothiazide\\nInteraction: mechanism\\n\\nSentence: Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. \\nDrug 1: digoxin\\nDrug 2: digoxin\\nInteraction: none\\n\\nSentence: Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.\\nDrug 1: Acetazolamide\\nDrug 2: amphetamine\\nInteraction: mechanism\\n\\nSentence: Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.\\nDrug1: Norpace\\nDrug2: quinidine\\nInteraction:\n",
       "27                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Sentence: Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.\\nDrug 1: ketoconazole\\nDrug 2: lapatinib\\nInteraction: mechanism\\n\\nSentence: Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.\\nDrug 1: Ketoconazole\\nDrug 2: vardenafil\\nInteraction: mechanism\\n\\nSentence: Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).\\nDrug 1: rifampin\\nDrug 2: Gleevec\\nInteraction: mechanism\\n\\nSentence: Phenytoin: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.\\nDrug 1: Phenytoin\\nDrug 2: lomefloxacin\\nInteraction: none\\n\\nSentence: Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.\\nDrug 1: mefenamic acid\\nDrug 2: mefenamic acid\\nInteraction: none\\n\\nSentence: Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.\\nDrug1: tolbutamide\\nDrug2: Aprepitant\\nInteraction:\n",
       "28         Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: perchlorate\\nDrug2: iodine-containing compounds\\nInteraction:\n",
       "29                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: estrogens\\nInteraction: none\\n\\nSentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\\nDrug 1: quinine\\nDrug 2: saquinavir\\nInteraction: mechanism\\n\\nSentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\\nDrug 1: triazolam\\nDrug 2: saquinavir\\nInteraction: mechanism\\n\\nSentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\\nDrug 1: disulfiram\\nDrug 2: fluoxetine\\nInteraction: none\\n\\nSentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\\nDrug 1: phenytoin\\nDrug 2: disulfiram\\nInteraction: mechanism\\n\\nSentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug1: clofibrate\\nDrug2: 5-fluorouracil\\nInteraction:\n",
       "30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: estrogens\\nInteraction: none\\n\\nSentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\\nDrug 1: quinine\\nDrug 2: saquinavir\\nInteraction: mechanism\\n\\nSentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\\nDrug 1: triazolam\\nDrug 2: saquinavir\\nInteraction: mechanism\\n\\nSentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\\nDrug 1: disulfiram\\nDrug 2: fluoxetine\\nInteraction: none\\n\\nSentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\\nDrug 1: phenytoin\\nDrug 2: disulfiram\\nInteraction: mechanism\\n\\nSentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug1: androgens\\nDrug2: 5-fluorouracil\\nInteraction:\n",
       "31                Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: thiocyanate\\nDrug2: somatostatin analogs\\nInteraction:\n",
       "32                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Sentence: Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.\\nDrug 1: xanthine derivatives\\nDrug 2: beta2-agonists.\\nInteraction: effect\\n\\nSentence: Other Drugs:Drugs such as quinidine, disopyramide, procainamide, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.\\nDrug 1: phenothiazines\\nDrug 2: antihistamines\\nInteraction: none\\n\\nSentence: Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.\\nDrug 1: NSAIDs\\nDrug 2: furosemide\\nInteraction: effect\\n\\nSentence: Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.\\nDrug 1: methysergide\\nDrug 2: naratriptan\\nInteraction: advice\\n\\nSentence: Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.\\nDrug 1: antihistamines\\nDrug 2: heparin sodium\\nInteraction: effect\\n\\nSentence: Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.\\nDrug1: spironolactone\\nDrug2: triamterene\\nInteraction:\n",
       "33                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Sentence: Methenamine therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.\\nDrug 1: amphetamines\\nDrug 2: methenamine\\nInteraction: mechanism\\n\\nSentence: Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.\\nDrug 1: atropine sulfate\\nDrug 2: MAO inhibitors\\nInteraction: other\\n\\nSentence: Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.\\nDrug 1: LEXAPRO\\nDrug 2: alcohol\\nInteraction: none\\n\\nSentence: Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.\\nDrug 1: psychotropic medications\\nDrug 2: LEXAPRO\\nInteraction: advice\\n\\nSentence: Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.\\nDrug 1: amphetamines\\nDrug 2: acidifying agents\\nInteraction: mechanism\\n\\nSentence: MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .\\nDrug1: MAO Inhibitors\\nDrug2: MAO inhibitor\\nInteraction:\n",
       "34                              Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: amiodarone\\nDrug2: heparin\\nInteraction:\n",
       "35                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: estrogens\\nInteraction: none\\n\\nSentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\\nDrug 1: quinine\\nDrug 2: saquinavir\\nInteraction: mechanism\\n\\nSentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\\nDrug 1: triazolam\\nDrug 2: saquinavir\\nInteraction: mechanism\\n\\nSentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\\nDrug 1: disulfiram\\nDrug 2: fluoxetine\\nInteraction: none\\n\\nSentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\\nDrug 1: phenytoin\\nDrug 2: disulfiram\\nInteraction: mechanism\\n\\nSentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug1: glucocorticoids\\nDrug2: tamoxifen\\nInteraction:\n",
       "36                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: estrogens\\nInteraction: none\\n\\nSentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\\nDrug 1: quinine\\nDrug 2: saquinavir\\nInteraction: mechanism\\n\\nSentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\\nDrug 1: triazolam\\nDrug 2: saquinavir\\nInteraction: mechanism\\n\\nSentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\\nDrug 1: disulfiram\\nDrug 2: fluoxetine\\nInteraction: none\\n\\nSentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\\nDrug 1: phenytoin\\nDrug 2: disulfiram\\nInteraction: mechanism\\n\\nSentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug1: meclofenamic acid\\nDrug2: tamoxifen\\nInteraction:\n",
       "37                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Sentence: Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.\\nDrug 1: itraconazole\\nDrug 2: gefitinib\\nInteraction: mechanism\\n\\nSentence: Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).\\nDrug 1: Gleevec\\nDrug 2: erythromycin\\nInteraction: advice\\n\\nSentence: Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.\\nDrug 1: esomeprazole\\nDrug 2: diazepam\\nInteraction: mechanism\\n\\nSentence: Based on the chemical resemblance of itraconazole and ketoconazole, coadministration of astemizole with itraconazole is contraindicated.\\nDrug 1: astemizole\\nDrug 2: itraconazole\\nInteraction: advice\\n\\nSentence: The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .\\nDrug 1: ENABLEX\\nDrug 2: ketoconazole\\nInteraction: advice\\n\\nSentence: Fluconazole and Ketoconazole: Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.\\nDrug1: Fluconazole\\nDrug2: Ketoconazole\\nInteraction:\n",
       "38  Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: aminoglutethimide\\nDrug2: b-adrenergic blocking agents\\nInteraction:\n",
       "39                 Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: aminoglutethimide\\nDrug2: nitroprusside\\nInteraction:\n",
       "40                       Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: amiodarone\\nDrug2: metoclopramide\\nInteraction:\n",
       "41                     Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: perchlorate\\nDrug2: chloral hydrate\\nInteraction:\n",
       "42                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\\nDrug 1: amlodipine\\nDrug 2: estrogens\\nInteraction: none\\n\\nSentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\\nDrug 1: quinine\\nDrug 2: saquinavir\\nInteraction: mechanism\\n\\nSentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\\nDrug 1: triazolam\\nDrug 2: saquinavir\\nInteraction: mechanism\\n\\nSentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\\nDrug 1: disulfiram\\nDrug 2: fluoxetine\\nInteraction: none\\n\\nSentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\\nDrug 1: phenytoin\\nDrug 2: disulfiram\\nInteraction: mechanism\\n\\nSentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\\nDrug1: asparaginase\\nDrug2: furosemide\\nInteraction:\n",
       "43                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Sentence: Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.\\nDrug 1: clozapine\\nDrug 2: encainide\\nInteraction: advice\\n\\nSentence: Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.\\nDrug 1: clozapine\\nDrug 2: propafenone\\nInteraction: advice\\n\\nSentence: Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.\\nDrug 1: fluoxetine\\nDrug 2: antipsychotics\\nInteraction: none\\n\\nSentence: Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.\\nDrug 1: risperidone\\nDrug 2: metoprolol\\nInteraction: none\\n\\nSentence: Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.\\nDrug 1: bupropion\\nDrug 2: nortriptyline\\nInteraction: advice\\n\\nSentence: Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.\\nDrug1: carbamazepine\\nDrug2: encainide\\nInteraction:\n",
       "44                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Sentence: Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.\\nDrug 1: INSPRA\\nDrug 2: lithium\\nInteraction: advice\\n\\nSentence: Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.\\nDrug 1: VIOXX\\nDrug 2: theophylline\\nInteraction: advice\\n\\nSentence: Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.\\nDrug 1: methotrexate\\nDrug 2: ciprofloxacin\\nInteraction: advice\\n\\nSentence: Nicardipine HCl usually does not alter the plasma levels of digoxin, however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine HCl is initiated.\\nDrug 1: digoxin\\nDrug 2: digoxin\\nInteraction: none\\n\\nSentence: Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.\\nDrug 1: Vitamin D\\nDrug 2: digitalis\\nInteraction: advice\\n\\nSentence: Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice.\\nDrug1: lithium\\nDrug2: lithium\\nInteraction:\n",
       "45                      Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: antithyroid drugs\\nDrug2: levodopa\\nInteraction:\n",
       "46                            Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: nicotinamide\\nDrug 2: protease inhibitors\\nInteraction: none\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: fluoxetine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: valproate\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: loratadine\\nInteraction: mechanism\\n\\nSentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\\nDrug 1: EQUETROTM\\nDrug 2: zileuton\\nInteraction: mechanism\\n\\nSentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\\nDrug1: thiocyanate\\nDrug2: levodopa\\nInteraction:\n",
       "47                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Sentence: 5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .\\nDrug 1: apomorphine\\nDrug 2: palonosetron\\nInteraction: advice\\n\\nSentence: 5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .\\nDrug 1: apomorphine\\nDrug 2: alosetron\\nInteraction: advice\\n\\nSentence: plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.\\nDrug 1: barbiturates\\nDrug 2: CMI\\nInteraction: mechanism\\n\\nSentence: plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.\\nDrug 1: tricyclic antidepressants\\nDrug 2: cimetidine\\nInteraction: mechanism\\n\\nSentence: The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.\\nDrug 1: antipsychotic drug\\nDrug 2: chlorpromazine\\nInteraction: none\\n\\nSentence: Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).\\nDrug1: Zarontin\\nDrug2: antiepileptic drugs\\nInteraction:"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dev_knn_500[['test_ready_prompt']]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentence: Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.\n",
      "Drug 1: bromocriptine mesylate\n",
      "Drug 2: ergot alkaloids\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: However, interactions may be expected, and UROXATRAL should NOT be used in combination with other alpha-blockers.\n",
      "Drug 1: UROXATRAL\n",
      "Drug 2: alpha-blockers\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.\n",
      "Drug 1: fentanyl\n",
      "Drug 2: beta blocker\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Population pharmacokinetic analyses revealed that MTX, NSAIDs, corticosteroids, and TNF blocking agents did not influence abatacept clearance.\n",
      "Drug 1: NSAIDs\n",
      "Drug 2: abatacept\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with potassium-sparing diuretics.\n",
      "Drug 1: nonsteroidal anti-inflammatory drugs\n",
      "Drug 2: potassium-sparing diuretics\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.\n",
      "Drug1: proton pump inhibitors\n",
      "Drug2: SPRYCEL\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.\n",
      "Drug 1: diflunisal\n",
      "Drug 2: methotrexate\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: However, interactions may be expected, and UROXATRAL should NOT be used in combination with other alpha-blockers.\n",
      "Drug 1: UROXATRAL\n",
      "Drug 2: alpha-blockers\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because of the potential for additive effects on systemic beta-blockade.\n",
      "Drug 1: Ocupress\n",
      "Drug 2: beta-adrenergic blocking agent\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.\n",
      "Drug 1: NSAIDs\n",
      "Drug 2: ACE-inhibitors\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.\n",
      "Drug 1: VIOXX\n",
      "Drug 2: theophylline\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: MAO inhibitors should be used with caution in patients receiving hydralazine.\n",
      "Drug1: MAO inhibitors\n",
      "Drug2: hydralazine\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Nicardipine HCl usually does not alter the plasma levels of digoxin, however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine HCl is initiated.\n",
      "Drug 1: digoxin\n",
      "Drug 2: digoxin\n",
      "Interaction: none\n",
      "\n",
      "Sentence: For example, when vitamin K antagonists are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.\n",
      "Drug 1: vitamin K antagonists\n",
      "Drug 2: nilutamide\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.\n",
      "Drug 1: VIOXX\n",
      "Drug 2: theophylline\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.\n",
      "Drug 1: diclofenac\n",
      "Drug 2: warfarin\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: If CEFOTAN and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated.\n",
      "Drug 1: CEFOTAN\n",
      "Drug 2: aminoglycoside\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.\n",
      "Drug1: Cyclosporine\n",
      "Drug2: Itraconazole\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: The concomitant use of diflunisal tablets and other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.\n",
      "Drug 1: diflunisal\n",
      "Drug 2: NSAIDs\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.\n",
      "Drug 1: BREVIBLOC\n",
      "Drug 2: warfarin\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Methotrexate - There is one report that methotrexate may decrease the possible effectiveness of supplemental L-glutamine for chemotherapy-induced mucositis.\n",
      "Drug 1: methotrexate\n",
      "Drug 2: L-glutamine\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.\n",
      "Drug 1: CRIXIVAN\n",
      "Drug 2: indinavir\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.\n",
      "Drug 1: LEXAPRO\n",
      "Drug 2: alcohol\n",
      "Interaction: none\n",
      "\n",
      "Sentence: There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.\n",
      "Drug1: ORENCIA\n",
      "Drug2: anakinra\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.\n",
      "Drug 1: almotriptan\n",
      "Drug 2: almotriptan\n",
      "Interaction: none\n",
      "\n",
      "Sentence: If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.\n",
      "Drug 1: indinavir\n",
      "Drug 2: budesonide\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).\n",
      "Drug 1: Gleevec\n",
      "Drug 2: erythromycin\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.\n",
      "Drug 1: dapsone\n",
      "Drug 2: itraconazole\n",
      "Interaction: none\n",
      "\n",
      "Sentence: The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .\n",
      "Drug 1: ENABLEX\n",
      "Drug 2: ketoconazole\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.\n",
      "Drug1: alosetron\n",
      "Drug2: telithromycin\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.\n",
      "Drug 1: Antihistamines\n",
      "Drug 2: tricyclic antidepressants\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.\n",
      "Drug 1: benzodiazepines\n",
      "Drug 2: barbiturates\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.\n",
      "Drug 1: antidepressants\n",
      "Drug 2: scopolamine\n",
      "Interaction: none\n",
      "\n",
      "Sentence: The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.\n",
      "Drug 1: alcohol\n",
      "Drug 2: narcotics\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).\n",
      "Drug 1: alcohol\n",
      "Drug 2: antihistamines\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.\n",
      "Drug1: butorphanol\n",
      "Drug2: antihistamines\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.\n",
      "Drug 1: nondepolarizing neuromuscular blocking agents\n",
      "Drug 2: phenytoin\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: 5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .\n",
      "Drug 1: apomorphine\n",
      "Drug 2: palonosetron\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: 5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .\n",
      "Drug 1: apomorphine\n",
      "Drug 2: alosetron\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.\n",
      "Drug 1: methysergide\n",
      "Drug 2: naratriptan\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.\n",
      "Drug 1: benzodiazepines\n",
      "Drug 2: barbiturates\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.\n",
      "Drug1: atropine\n",
      "Drug2: pralidoxime\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.\n",
      "Drug 1: lithium\n",
      "Drug 2: ACE inhibitors\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Anticoagulants: There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.\n",
      "Drug 1: erythromycin\n",
      "Drug 2: anticoagulants\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.\n",
      "Drug 1: cytotoxic agents\n",
      "Drug 2: allopurinol\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.\n",
      "Drug 1: cyclophosphamide\n",
      "Drug 2: allopurinol\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.\n",
      "Drug 1: erythromycin\n",
      "Drug 2: digoxin\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.\n",
      "Drug1: ACE inhibitors\n",
      "Drug2: lithium\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.\n",
      "Drug 1: alcohol\n",
      "Drug 2: narcotics\n",
      "Interaction: none\n",
      "\n",
      "Sentence: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.\n",
      "Drug 1: sulfonamides\n",
      "Drug 2: monoamine oxidase inhibitors\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.\n",
      "Drug 1: Antihistamines\n",
      "Drug 2: tricyclic antidepressants\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Other Drugs:Drugs such as quinidine, disopyramide, procainamide, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.\n",
      "Drug 1: phenothiazines\n",
      "Drug 2: antihistamines\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.\n",
      "Drug 1: xanthine derivatives\n",
      "Drug 2: beta2-agonists.\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.\n",
      "Drug1: benzodiazepines\n",
      "Drug2: antidepressants\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.\n",
      "Drug 1: Lodine\n",
      "Drug 2: thiazides\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.\n",
      "Drug 1: tricyclic anti-depressants\n",
      "Drug 2: bepridil hydrochloride\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.\n",
      "Drug 1: nondepolarizing neuromuscular blocking agents\n",
      "Drug 2: phenytoin\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.\n",
      "Drug 1: Fondaparinux\n",
      "Drug 2: piroxicam\n",
      "Interaction: none\n",
      "\n",
      "Sentence: This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder. \n",
      "Drug 1: phenytoin\n",
      "Drug 2: quetiapine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.\n",
      "Drug1: verapamil\n",
      "Drug2: dofetilide\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.\n",
      "Drug 1: alcohol\n",
      "Drug 2: DILAUDID\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.\n",
      "Drug 1: narcotic analgesic\n",
      "Drug 2: phenothiazines\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).\n",
      "Drug 1: Nabilone\n",
      "Drug 2: alcohol\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).\n",
      "Drug 1: Nabilone\n",
      "Drug 2: CNS depressants\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).\n",
      "Drug 1: Nabilone\n",
      "Drug 2: barbiturates\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.\n",
      "Drug1: alcohol\n",
      "Drug2: hydrocodone\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.\n",
      "Drug 1: atropine sulfate\n",
      "Drug 2: MAO inhibitors\n",
      "Interaction: other\n",
      "\n",
      "Sentence: Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.\n",
      "Drug 1: mefenamic acid\n",
      "Drug 2: mefenamic acid\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.\n",
      "Drug 1: Ketoconazole\n",
      "Drug 2: vardenafil\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.\n",
      "Drug 1: alprazolam\n",
      "Drug 2: Fluvoxamine\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.\n",
      "Drug 1: Naproxen\n",
      "Drug 2: naproxen\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.\n",
      "Drug1: diflunisal\n",
      "Drug2: acetaminophen\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.\n",
      "Drug 1: anesthetics\n",
      "Drug 2: tricyclic antidepressants\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Other Drugs:Drugs such as quinidine, disopyramide, procainamide, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.\n",
      "Drug 1: phenothiazines\n",
      "Drug 2: antihistamines\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and beta-blockers.)\n",
      "Drug 1: clonidine\n",
      "Drug 2: calcium channel blockers\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and beta-blockers.)\n",
      "Drug 1: clonidine\n",
      "Drug 2: beta-blockers\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.\n",
      "Drug 1: LEXAPRO\n",
      "Drug 2: alcohol\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.\n",
      "Drug1: tricyclic antidepressants\n",
      "Drug2: guanethidine\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.\n",
      "Drug 1: epinephrine\n",
      "Drug 2: monoamine oxidase inhibitors\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.\n",
      "Drug 1: epinephrine\n",
      "Drug 2: tricyclic antidepressants\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.\n",
      "Drug 1: norepinephrine\n",
      "Drug 2: tricyclic antidepressants\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.\n",
      "Drug 1: epinephrine\n",
      "Drug 2: tricyclic antidepressants\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .\n",
      "Drug 1: doxapram\n",
      "Drug 2: sympathomimetic\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.\n",
      "Drug1: norepinephrine\n",
      "Drug2: monoamine oxidase inhibitors\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.\n",
      "Drug 1: antihistamines\n",
      "Drug 2: heparin sodium\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Drug/ Laboratory Test Interactions Certain endocrine and liver function tests may be affected by estrogen-containing oral contraceptives.\n",
      "Drug 1: estrogen\n",
      "Drug 2: contraceptives\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.\n",
      "Drug 1: Diclofenac\n",
      "Drug 2: diuretics\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.\n",
      "Drug 1: xanthine derivatives\n",
      "Drug 2: beta2-agonists.\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Acetazolamide may increase the effects of other folic acid antagonists.\n",
      "Drug 1: Acetazolamide\n",
      "Drug 2: folic acid antagonists\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.\n",
      "Drug1: hormonal contraceptives\n",
      "Drug2: coumarin derivatives\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.\n",
      "Drug 1: erythromycin\n",
      "Drug 2: dihydroergotamine\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.\n",
      "Drug 1: methysergide\n",
      "Drug 2: naratriptan\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.\n",
      "Drug 1: erythromycin\n",
      "Drug 2: digoxin\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Caution is advised in patients receiving concomitant high-dose aspirin and carbonic anhydrase inhibitors, as anorexia, tachypnea, lethargy and coma have been rarely reported due to a possible drug interaction.\n",
      "Drug 1: aspirin\n",
      "Drug 2: carbonic anhydrase inhibitors\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam.\n",
      "Drug 1: loxapine\n",
      "Drug 2: lorazepam\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.\n",
      "Drug1: erythromycin\n",
      "Drug2: ergotamine\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.\n",
      "Drug 1: Antihistamines\n",
      "Drug 2: tricyclic antidepressants\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.\n",
      "Drug 1: benzodiazepines\n",
      "Drug 2: barbiturates\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.\n",
      "Drug 1: antidepressants\n",
      "Drug 2: scopolamine\n",
      "Interaction: none\n",
      "\n",
      "Sentence: The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.\n",
      "Drug 1: alcohol\n",
      "Drug 2: narcotics\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).\n",
      "Drug 1: alcohol\n",
      "Drug 2: antihistamines\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.\n",
      "Drug1: butorphanol\n",
      "Drug2: tranquilizers\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.\n",
      "Drug 1: thiazides\n",
      "Drug 2: amphetamine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.\n",
      "Drug 1: tetracycline\n",
      "Drug 2: digoxin\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.\n",
      "Drug 1: Phenobarbital\n",
      "Drug 2: vitamin D\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).\n",
      "Drug 1: Quinidine\n",
      "Drug 2: quinidine\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.\n",
      "Drug 1: acetaminophen\n",
      "Drug 2: BUSULFEX\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.\n",
      "Drug1: allopurinol\n",
      "Drug2: chlorpropamide\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.\n",
      "Drug 1: paclitaxel\n",
      "Drug 2: doxorubicin\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.\n",
      "Drug 1: tetracycline\n",
      "Drug 2: digoxin\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.\n",
      "Drug 1: phenytoin\n",
      "Drug 2: corticosteroids\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.\n",
      "Drug 1: HMG-CoA reductase inhibitor\n",
      "Drug 2: ketoconazole\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.\n",
      "Drug 1: nondepolarizing neuromuscular blocking agents\n",
      "Drug 2: phenytoin\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.\n",
      "Drug1: rifampin\n",
      "Drug2: corticosteroids\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. \n",
      "Drug 1: digoxin\n",
      "Drug 2: digoxin\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.\n",
      "Drug 1: bosentan\n",
      "Drug 2: glyburide\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.\n",
      "Drug 1: Ketoconazole\n",
      "Drug 2: vardenafil\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Phenytoin: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.\n",
      "Drug 1: Phenytoin\n",
      "Drug 2: lomefloxacin\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.\n",
      "Drug 1: atorvastatin\n",
      "Drug 2: contraceptive\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: (See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.\n",
      "Drug1: Femara\n",
      "Drug2: tamoxifen\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Phenytoin: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.\n",
      "Drug 1: Phenytoin\n",
      "Drug 2: lomefloxacin\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.\n",
      "Drug 1: mefenamic acid\n",
      "Drug 2: mefenamic acid\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.\n",
      "Drug 1: Ketoconazole\n",
      "Drug 2: vardenafil\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.\n",
      "Drug 1: BREVIBLOC\n",
      "Drug 2: morphine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.\n",
      "Drug 1: ketoconazole\n",
      "Drug 2: lapatinib\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.\n",
      "Drug1: nitrates\n",
      "Drug2: vardenafil\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: nicotinamide\n",
      "Drug 2: protease inhibitors\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: fluoxetine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: valproate\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: loratadine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: zileuton\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.\n",
      "Drug1: EQUETROTM\n",
      "Drug2: nortriptyline\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.\n",
      "Drug 1: Ketoconazole\n",
      "Drug 2: vardenafil\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.\n",
      "Drug 1: aspirin\n",
      "Drug 2: valdecoxib\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. \n",
      "Drug 1: digoxin\n",
      "Drug 2: digoxin\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.\n",
      "Drug 1: dextromethorphan\n",
      "Drug 2: valdecoxib\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.\n",
      "Drug 1: BREVIBLOC\n",
      "Drug 2: morphine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.\n",
      "Drug1: anastrozole\n",
      "Drug2: tamoxifen\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: nicotinamide\n",
      "Drug 2: protease inhibitors\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: fluoxetine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: valproate\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: loratadine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: zileuton\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.\n",
      "Drug1: EQUETROTM\n",
      "Drug2: felbamate\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: nicotinamide\n",
      "Drug 2: protease inhibitors\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: fluoxetine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: valproate\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: loratadine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: zileuton\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.\n",
      "Drug1: EQUETROTM\n",
      "Drug2: haloperidol\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: - Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine\n",
      "Drug 1: phenytoin\n",
      "Drug 2: alcohol\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;\n",
      "Drug 1: colestipol\n",
      "Drug 2: thiazide diuretics\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol\n",
      "Drug 1: Tricyclic antidepressants\n",
      "Drug 2: tramadol\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Enhanced theophylline clearance secondary to phenytoin therapy.\r\n",
      "\n",
      "Drug 1: theophylline\n",
      "Drug 2: phenytoin\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;\n",
      "Drug 1: Cyclopentolate\n",
      "Drug 2: carbachol\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;\n",
      "Drug1: Amphetamines\n",
      "Drug2: phenobarbital\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.\n",
      "Drug 1: BREVIBLOC\n",
      "Drug 2: morphine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.\n",
      "Drug 1: Naproxen\n",
      "Drug 2: naproxen\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.\n",
      "Drug 1: diflunisal\n",
      "Drug 2: hydrochlorothiazide\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. \n",
      "Drug 1: digoxin\n",
      "Drug 2: digoxin\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.\n",
      "Drug 1: Acetazolamide\n",
      "Drug 2: amphetamine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.\n",
      "Drug1: Norpace\n",
      "Drug2: quinidine\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.\n",
      "Drug 1: ketoconazole\n",
      "Drug 2: lapatinib\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.\n",
      "Drug 1: Ketoconazole\n",
      "Drug 2: vardenafil\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).\n",
      "Drug 1: rifampin\n",
      "Drug 2: Gleevec\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Phenytoin: No significant differences were observed in mean phenytoin AUC, C max , C min or T max (although C max increased by 11%) when extended phenytoin sodium capsules (100 mg tid) were coadministered with lomefloxacin (400 mg qd) for five days in 15 healthy males.\n",
      "Drug 1: Phenytoin\n",
      "Drug 2: lomefloxacin\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.\n",
      "Drug 1: mefenamic acid\n",
      "Drug 2: mefenamic acid\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.\n",
      "Drug1: tolbutamide\n",
      "Drug2: Aprepitant\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: nicotinamide\n",
      "Drug 2: protease inhibitors\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: fluoxetine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: valproate\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: loratadine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: zileuton\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\n",
      "Drug1: perchlorate\n",
      "Drug2: iodine-containing compounds\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\n",
      "Drug 1: amlodipine\n",
      "Drug 2: estrogens\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\n",
      "Drug 1: quinine\n",
      "Drug 2: saquinavir\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\n",
      "Drug 1: triazolam\n",
      "Drug 2: saquinavir\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\n",
      "Drug 1: disulfiram\n",
      "Drug 2: fluoxetine\n",
      "Interaction: none\n",
      "\n",
      "Sentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\n",
      "Drug 1: phenytoin\n",
      "Drug 2: disulfiram\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\n",
      "Drug1: clofibrate\n",
      "Drug2: 5-fluorouracil\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\n",
      "Drug 1: amlodipine\n",
      "Drug 2: estrogens\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\n",
      "Drug 1: quinine\n",
      "Drug 2: saquinavir\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\n",
      "Drug 1: triazolam\n",
      "Drug 2: saquinavir\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\n",
      "Drug 1: disulfiram\n",
      "Drug 2: fluoxetine\n",
      "Interaction: none\n",
      "\n",
      "Sentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\n",
      "Drug 1: phenytoin\n",
      "Drug 2: disulfiram\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\n",
      "Drug1: androgens\n",
      "Drug2: 5-fluorouracil\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: nicotinamide\n",
      "Drug 2: protease inhibitors\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: fluoxetine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: valproate\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: loratadine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: zileuton\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\n",
      "Drug1: thiocyanate\n",
      "Drug2: somatostatin analogs\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.\n",
      "Drug 1: xanthine derivatives\n",
      "Drug 2: beta2-agonists.\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Other Drugs:Drugs such as quinidine, disopyramide, procainamide, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.\n",
      "Drug 1: phenothiazines\n",
      "Drug 2: antihistamines\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.\n",
      "Drug 1: NSAIDs\n",
      "Drug 2: furosemide\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.\n",
      "Drug 1: methysergide\n",
      "Drug 2: naratriptan\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.\n",
      "Drug 1: antihistamines\n",
      "Drug 2: heparin sodium\n",
      "Interaction: effect\n",
      "\n",
      "Sentence: Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.\n",
      "Drug1: spironolactone\n",
      "Drug2: triamterene\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Methenamine therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.\n",
      "Drug 1: amphetamines\n",
      "Drug 2: methenamine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.\n",
      "Drug 1: atropine sulfate\n",
      "Drug 2: MAO inhibitors\n",
      "Interaction: other\n",
      "\n",
      "Sentence: Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.\n",
      "Drug 1: LEXAPRO\n",
      "Drug 2: alcohol\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.\n",
      "Drug 1: psychotropic medications\n",
      "Drug 2: LEXAPRO\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.\n",
      "Drug 1: amphetamines\n",
      "Drug 2: acidifying agents\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .\n",
      "Drug1: MAO Inhibitors\n",
      "Drug2: MAO inhibitor\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: nicotinamide\n",
      "Drug 2: protease inhibitors\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: fluoxetine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: valproate\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: loratadine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: zileuton\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\n",
      "Drug1: amiodarone\n",
      "Drug2: heparin\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\n",
      "Drug 1: amlodipine\n",
      "Drug 2: estrogens\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\n",
      "Drug 1: quinine\n",
      "Drug 2: saquinavir\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\n",
      "Drug 1: triazolam\n",
      "Drug 2: saquinavir\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\n",
      "Drug 1: disulfiram\n",
      "Drug 2: fluoxetine\n",
      "Interaction: none\n",
      "\n",
      "Sentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\n",
      "Drug 1: phenytoin\n",
      "Drug 2: disulfiram\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\n",
      "Drug1: glucocorticoids\n",
      "Drug2: tamoxifen\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\n",
      "Drug 1: amlodipine\n",
      "Drug 2: estrogens\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\n",
      "Drug 1: quinine\n",
      "Drug 2: saquinavir\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\n",
      "Drug 1: triazolam\n",
      "Drug 2: saquinavir\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\n",
      "Drug 1: disulfiram\n",
      "Drug 2: fluoxetine\n",
      "Interaction: none\n",
      "\n",
      "Sentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\n",
      "Drug 1: phenytoin\n",
      "Drug 2: disulfiram\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\n",
      "Drug1: meclofenamic acid\n",
      "Drug2: tamoxifen\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.\n",
      "Drug 1: itraconazole\n",
      "Drug 2: gefitinib\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).\n",
      "Drug 1: Gleevec\n",
      "Drug 2: erythromycin\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.\n",
      "Drug 1: esomeprazole\n",
      "Drug 2: diazepam\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Based on the chemical resemblance of itraconazole and ketoconazole, coadministration of astemizole with itraconazole is contraindicated.\n",
      "Drug 1: astemizole\n",
      "Drug 2: itraconazole\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .\n",
      "Drug 1: ENABLEX\n",
      "Drug 2: ketoconazole\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Fluconazole and Ketoconazole: Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.\n",
      "Drug1: Fluconazole\n",
      "Drug2: Ketoconazole\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: nicotinamide\n",
      "Drug 2: protease inhibitors\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: fluoxetine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: valproate\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: loratadine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: zileuton\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\n",
      "Drug1: aminoglutethimide\n",
      "Drug2: b-adrenergic blocking agents\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: nicotinamide\n",
      "Drug 2: protease inhibitors\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: fluoxetine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: valproate\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: loratadine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: zileuton\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\n",
      "Drug1: aminoglutethimide\n",
      "Drug2: nitroprusside\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: nicotinamide\n",
      "Drug 2: protease inhibitors\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: fluoxetine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: valproate\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: loratadine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: zileuton\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\n",
      "Drug1: amiodarone\n",
      "Drug2: metoclopramide\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: nicotinamide\n",
      "Drug 2: protease inhibitors\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: fluoxetine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: valproate\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: loratadine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: zileuton\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\n",
      "Drug1: perchlorate\n",
      "Drug2: chloral hydrate\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.\n",
      "Drug 1: amlodipine\n",
      "Drug 2: estrogens\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\n",
      "Drug 1: quinine\n",
      "Drug 2: saquinavir\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;\n",
      "Drug 1: triazolam\n",
      "Drug 2: saquinavir\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\n",
      "Drug 1: disulfiram\n",
      "Drug 2: fluoxetine\n",
      "Interaction: none\n",
      "\n",
      "Sentence: The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone\n",
      "Drug 1: phenytoin\n",
      "Drug 2: disulfiram\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.\n",
      "Drug1: asparaginase\n",
      "Drug2: furosemide\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.\n",
      "Drug 1: clozapine\n",
      "Drug 2: encainide\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.\n",
      "Drug 1: clozapine\n",
      "Drug 2: propafenone\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.\n",
      "Drug 1: fluoxetine\n",
      "Drug 2: antipsychotics\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.\n",
      "Drug 1: risperidone\n",
      "Drug 2: metoprolol\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.\n",
      "Drug 1: bupropion\n",
      "Drug 2: nortriptyline\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.\n",
      "Drug1: carbamazepine\n",
      "Drug2: encainide\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.\n",
      "Drug 1: INSPRA\n",
      "Drug 2: lithium\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.\n",
      "Drug 1: VIOXX\n",
      "Drug 2: theophylline\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.\n",
      "Drug 1: methotrexate\n",
      "Drug 2: ciprofloxacin\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Nicardipine HCl usually does not alter the plasma levels of digoxin, however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine HCl is initiated.\n",
      "Drug 1: digoxin\n",
      "Drug 2: digoxin\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.\n",
      "Drug 1: Vitamin D\n",
      "Drug 2: digitalis\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice.\n",
      "Drug1: lithium\n",
      "Drug2: lithium\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: nicotinamide\n",
      "Drug 2: protease inhibitors\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: fluoxetine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: valproate\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: loratadine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: zileuton\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\n",
      "Drug1: antithyroid drugs\n",
      "Drug2: levodopa\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: nicotinamide\n",
      "Drug 2: protease inhibitors\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: fluoxetine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: valproate\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: loratadine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.\n",
      "Drug 1: EQUETROTM\n",
      "Drug 2: zileuton\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.\n",
      "Drug1: thiocyanate\n",
      "Drug2: levodopa\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n",
      "Sentence: 5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .\n",
      "Drug 1: apomorphine\n",
      "Drug 2: palonosetron\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: 5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .\n",
      "Drug 1: apomorphine\n",
      "Drug 2: alosetron\n",
      "Interaction: advice\n",
      "\n",
      "Sentence: plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.\n",
      "Drug 1: barbiturates\n",
      "Drug 2: CMI\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.\n",
      "Drug 1: tricyclic antidepressants\n",
      "Drug 2: cimetidine\n",
      "Interaction: mechanism\n",
      "\n",
      "Sentence: The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.\n",
      "Drug 1: antipsychotic drug\n",
      "Drug 2: chlorpromazine\n",
      "Interaction: none\n",
      "\n",
      "Sentence: Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).\n",
      "Drug1: Zarontin\n",
      "Drug2: antiepileptic drugs\n",
      "Interaction:\n",
      "label\n",
      "----------------------------------------------------------------------------------------------------\n"
     ]
    }
   ],
   "source": [
    "for i, row in dev_knn_500[dev_knn_500['label'] != dev_knn_500['ddi_test_prompts_random_42.5.50.perm_4.KNN_500_balancedsubset']].iterrows():\n",
    "    \n",
    "    print(row['test_ready_prompt'])\n",
    "    print('label')\n",
    "    print('-'*100)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "scispacy",
   "language": "python",
   "name": "scispacy"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
